Clinical Trial Update: Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on a combination of ranibizumab and verteporfin for neovascular age-related macular degeneration; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)
• Visudyne (verteporfin)

Snippet

Sponsor: Novartis Korea Ltd. | Conditions: Neovascular Age-related Macular Degeneration | Phase 3 | Status: COMPLETED